Naramig (Naratriptan Hydrochloride)

Naratriptan Hydrochloride, the active ingredient in Naramig, is a selective serotonin 5‑HT1B/1D receptor agonist (triptan) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults. Naramig is marketed in the European Union and meets the quality standards required for prescription medicines.

GNH USA supplies Naramig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan Hydrochloride belongs to the triptan class and is used to treat acute migraine episodes.

- Migraine without aura: provides rapid relief of headache and associated symptoms. - Migraine with aura: helps abort attacks after the onset of visual or sensory disturbances. - Acute migraine attack: reduces pain intensity and improves functional ability during an episode.

Common side effects are generally mild and transient, while serious or rare reactions require immediate medical attention.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness. - Fatigue: feeling unusually tired. - Dry mouth: reduced salivation. - Tingling or numbness: usually in the extremities. - Flushing: warm sensation and reddening of the skin.

Serious or Rare Side Effects: - Chest pain or tightness: possible cardiac ischemia. - Serotonin syndrome: agitation, hyperthermia, tremor. - Severe hypertension: sudden increase in blood pressure. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Ischemic colitis: abdominal pain with blood in stool. - Persistent visual disturbances: prolonged aura symptoms.

Before prescribing Naramig, clinicians should evaluate patient history and comorbid conditions.

- Cardiovascular assessment: avoid in patients with uncontrolled hypertension, coronary artery disease, or history of stroke. - Drug history review: caution with other serotonergic agents to reduce serotonin syndrome risk. - Pregnancy considerations: safety not established; use only if potential benefit outweighs risk. - Breastfeeding: limited data; weigh benefits against possible infant exposure. - Renal or hepatic impairment: adjust use based on clinical judgment. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Naratriptan Hydrochloride can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - SSRIs, SNRIs, or other serotonergic antidepressants: heightened serotonin toxicity. - Ergot alkaloids or other triptans: additive vasoconstriction leading to cardiovascular events. - Certain antihypertensives (e.g., propranolol): may elevate naratriptan plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase drug exposure. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Diuretics: monitor blood pressure changes. - Antihistamines: may enhance dizziness or sedation.